Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Bardia · SciRah

Researcher profile · Semantic Scholar

A. Bardia

Share profile

A. Bardia — researcher profile on SciRah

h-index: 87
Works: 927
Citations: 36K

Most-cited papers

Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial
A. Bardia, P. Schmid, M. Martín, S. Hurvitz +17 more
2026Clinical Cancer Research27 citations
Semantic Scholar
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
Yael Bar, Geoffrey G. Fell, A. Dedeoglu, Natalie Moffett +8 more
2025npj Breast Cancer21 citations Open access
Semantic Scholar
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06
R. Shami, R. Salgado, A. Bardia, G. Curigliano +23 more
2025ESMO Open10 citations Open access
Semantic Scholar
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer
Maxwell R. Lloyd, Rosario Chica-Parrado, C. Weipert, Todd Knepper +22 more
2025EBioMedicine8 citations Open access
Semantic Scholar
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.
G. Curigliano, X. Hu, R. Dent, K. Yonemori +13 more
2026Annals of Oncology7 citations Open access
Semantic Scholar
Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.
N. Turner, K. Jhaveri, A. Bardia, N. Niikura +15 more
2026Journal of Clinical Oncology5 citations
Semantic Scholar
LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes
J. Crown, D. Stroyakovskiy, D. Yardley, C.-S. Huang +16 more
2025Annals of Oncology5 citations
Semantic Scholar
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer
Bogang Wu, W. Thant, E. Bitman, Ting Liu +19 more
2026Journal for ImmunoTherapy of Cancer4 citations Open access
Semantic Scholar
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer
A. Collier, S. Hilz, A. Chibly, Chunzhe Duan +10 more
2026Nature Communications3 citations
Semantic Scholar
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia
H. Rugo, S. Tolaney, J. Cortés, F. Marmé +9 more
2026ESMO Open3 citations Open access
Semantic Scholar
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study
H. Rugo, K. Jhaveri, S. Pernas, B. Pistilli +20 more
2026ESMO Open3 citations Open access
Semantic Scholar
Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer
G. Gupta, A. Ho, F. Gharibpoor, Y. Abdou +31 more
2026Clinical Cancer Research2 citations
Semantic Scholar
Abstract PD5-01: Personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+/HER2- early-stage breast cancer (LEADER)
A. Medford, C. Scalise, S. Dhulekar, Z. Smolar +18 more
2026Clinical Cancer Research2 citations
Semantic Scholar
ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i).
C. Barrios, S. Hurvitz, S. Tolaney, J. Cortés +15 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.
S. Wander, Maxwell R. Lloyd, J. Keenan, Elizabeth C. Scott +26 more
2026The Lancet Oncology2 citations
Semantic Scholar
Abstract 1711: Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study
S. Alkassis, M. Lipsyc-Sharf, Catherine Hegarty-Traverso, J. Mercer +14 more
2025Cancer Research2 citations
Semantic Scholar
A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer
A. Beumer, Martha Carlson, A. L. Arcuri, J. Maués +12 more
2026Journal of Patient Experience1 citations Open access
Semantic Scholar
Activating a B cell immune response regresses immunologically cold tumours
Heena Aggarwal, Nimish Gupta, Aniruddha Sengupta, Arindam Sarkar +14 more
2026Nature Nanotechnology1 citations
Semantic Scholar
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10
H. Rugo, P. Schmid, Javier Cortés, T. Takano +12 more
2026Future Oncology1 citations Open access
Semantic Scholar
Prognostic impact of PIK3CA amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer (MBC).
L. Foffano, Andrew A. Davis, C. Reduzzi, E. Podany +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Abstract PS4-06-28: Initial clinical and pharmacology results from START-002: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T cell agonist, in combination with sacituzumab govitecan in patients with mTNBC or HR+/HER2- mBC
S. Isakoff, A. Martynova, P. Bedard, A. Bardia +13 more
2026Clinical Cancer Research1 citations
Semantic Scholar
PS5-09-16: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in patients with metastatic TNBC or HR+/HER2- MBC (START-002 trial)
S. Isakoff, P. Bedard, A. Martynova, A. Bardia +13 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Abstract RF6-05: Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors in the phase 3 ASCENT-03 study
K. Punie, S. Tolaney, A. Bardia, S. Hurvitz +15 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Prognostic Risk Refinement using Artificial Intelligence in HR+/HER2- Early Breast Cancer: Implications for CDK4/6 Eligibility Criteria
N. McAndrew, C. Ma, A. Davis, E. Chiru +7 more
2026medRxiv1 citations
Semantic Scholar
Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
P. Schmid, C. Geyer, Miguel Martín, S. Hurvitz +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival
E. Podany, L. Foffano, L. Gerratana, A. Medford +18 more
2026Breast Cancer Research and Treatment1 citations Open access
Semantic Scholar
Abstract PD5-05: Impact of circulating tumor DNA (ctDNA) surveillance on quality of life (QoL) for patients with early-stage breast cancer (EBC): prospective I-SURV study
C. Cheng, S. S. Seyeddi, E. Brierley-Green, D. Vaghashia +16 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.
S. Wander, C. Weipert, L. Cabel, J. Liao +4 more
2026npj Breast Cancer1 citations Open access
Semantic Scholar
Abstract PS3-08-26: Comparison of Breast Cancer Index Scores from Core-Needle Biopsies versus Surgical Excisions in Early-Stage Breast Cancer
N. Kapoor, N. Siuliukina, Y. Zhang, A. Anderson +5 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC).
S. Chia, P. Fasching, John Crown, D. Slamon +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
A retrospective analysis of metaplastic triple negative breast cancer response to sacituzumab govitecan and candidacy for targeted therapy.
Shivahamy Maheswaran, A. Dedeoglu, A. Niemierko, R. Abelman +8 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-(L)1)
M. Reinisch, J. Cortés, A. Bardia, K. Punie +16 more
2026Senologie - Zeitschrift für Mammadiagnostik und -therapie0 citations
Semantic Scholar
Abstract PS3-06-03: Refining adjuvant CDK4/6 inhibitor eligibility in early HR+ HER2- breast cancer with artificial intelligence
N. Mcandrew, E. Chiru, E. Senkus-Konefka, A. Bardia +4 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS1-05-16: Patient understanding and impact on quality of life of serial minimal residual disease testing in patients with early-stage breast cancer
S. Tapiavala, I. Grigsby, N. Bagegni, F. Fa'ak +12 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract CT225: ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study
A. Bardia, V. Kaklamani, J. O'Shaughnessy, P. Schmid +13 more
2026Cancer Research0 citations
Semantic Scholar
Extreme ESR1 Polyclonality, Mutation Dynamics, and Effects on Treatment Outcomes in Patients with ER+ Metastatic Breast Cancer
Elena M. Michaels, T. O'Meara, E. Podany, M. Lipsyc-Sharf +14 more
2026Research Square0 citations Open access
Semantic Scholar
Abstract PS5-02-13: Journeying Through the Spectrum of HER2 Expression Breast Cancer Clinic: Education Outcomes on Guiding Treatment Decisions
T. Ackbarali, K. Jones, A. Bardia, S. Hurvitz
2026Clinical Cancer Research0 citations
Semantic Scholar
Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer
Shi-Liang Zhang, K. Queen, N. Duggirala, Eric H. Yang +12 more
2026npj Breast Cancer0 citations Open access
Semantic Scholar
Abstract PS4-04-26: Anti-tumor activity of ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, in tamoxifen and trastuzumab resistant breast cancer models
A. Kamal, Amanda S. Chin, S. Mukherjee, J. Li +7 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS1-13-24: Safety analysis of ASCENT-03, a phase 3 study of sacituzumab govitecan (SG) vs chemotherapy (chemo) for previously untreated advanced triple-negative breast cancer (TNBC) in patients (pts) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i)
S. Hurvitz, A. Bardia, S. Tolaney, K. Punie +21 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract C040: Sustained lymphopenia during neoadjuvant chemo-immunotherapy is associated with worse outcomes in early triple-negative breast cancer
A. LeVee, E. Yang, K. Tsai, N. Baclig +15 more
2026Cancer immunology research0 citations
Semantic Scholar
Abstract PS3-08-09: Postpartum breast cancer as a potential driver of increased 21-gene recurrence score (RS) and RS category for node-positive HR+/HER2- breast cancer
S. Zhang, K. Queen, M. Lipsyc-Sharf, N. Duggirala +3 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Minimal residual disease ctDNA testing in metastatic breast cancer patients with no radiological evidence of disease: Potentialclinical utility from real-worlddata.
C. Gianni, I. Azzali, O. Rieur, A. Medford +15 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract PS2-07-25: Genomic biomarkers of response to ipatasertib in hormone receptor-positive, HER2-negative metastatic breast cancer
Z. Bagheri, M. Lloyd, G. Fell, E. Scott +16 more
2026Clinical Cancer Research0 citations
Semantic Scholar
ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor–positive (ER+), HER2-negative (HER2−), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
A. Bardia, V. Kaklamani, J. O'Shaughnessy, P. Schmid +13 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Lymphopenia in breast cancer and association with clinical outcomes: An analysis from over 30,000 patients.
A. LeVee, Eric Yang, Shi-Liang Zhang, Gavin Hui +10 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract PS1-10-17: Progression-free Survival by Local Investigators vs. Blinded Independent Central Review in Hormone-Positive, HER2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-analysis
L. Ravani, Z. Bagheri, K. Kalinsky, H. Burstein +4 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Elacestrant in combination with capivasertib in patients with ER+/HER2− advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.
W. McHayleh, S. Tolaney, V. Kaklamani, M. George +12 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Targeting cellular senescence to enhance skeletal muscle recovery in survivors of breast cancer: An ancillary study of the phase II randomized PROFFi clinical trial.
Jing-Ran Ji, Y. Zektser, M. Lipsyc-Sharf, A. LeVee +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract PS2-07-02: Tissue-free epigenomic circulating tumor DNA (ctDNA) analysis pre- and post-surgery in early breast cancer: clinical features and prognostic utility
A. Medford, J. Knape, D. Dustin, A. Dedeoglu +14 more
2026Clinical Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Lipsyc-Sharf×11
Invite
M. Lipsyc-Sharf — researcher profile on SciRah
A. Medford×9
Invite
A. Medford — researcher profile on SciRah
H. Rugo×9
Invite
H. Rugo — researcher profile on SciRah
S. Hurvitz×8
Invite
S. Hurvitz — researcher profile on SciRah

×8

Invite

S. Tolaney — researcher profile on SciRah

Invite

S. Isakoff — researcher profile on SciRah

Invite

E. Podany — researcher profile on SciRah

Invite

B. Xu — researcher profile on SciRah

Invite

S. Wander — researcher profile on SciRah

P. Perez-Moreno×4

Invite

P. Perez-Moreno — researcher profile on SciRah

Cynthia X. Ma×4

Invite

Cynthia X. Ma — researcher profile on SciRah

Invite

L. Ellisen — researcher profile on SciRah